Simplifying Global Compliance
Canada Resets Clinical Trial Application Requirements
Clinical Trials Advisor
Sponsors seeking to import drugs into Canada for trials must provide Health Canada with a “No Objection Letter” to facilitate shipment and demonstrate regulatory compliance, according to a November draft guidance on clinical trial applications (CTA).
To View This Article:
Subscribe To Clinical Trials Advisor
Buy This Article Now
Copyright ©2018. All Rights Reserved.
Design, CMS, Hosting & Web Development :: ePublishing